AIRNA Raises Oversubscribed $60 Million Financing to Advance …

Jul 31, 2024 · Cambridge, MA, USA and Tübingen, Germany, July 31, 2024 – AIRNA, a biotech company pioneering RNA editing therapeutics to restore the health of patients with rare and …

CouponFollow Extension

$60
OFF

AIRNA Raises Oversubscribed $60 Million Financing To Advance …

1 week from now

Jul 31, 2024 · Cambridge, MA, USA and Tübingen, Germany, July 31, 2024 – AIRNA, a biotech company pioneering RNA editing therapeutics to restore the health of patients with rare and …

airna.com

$60
OFF

Biotech Startup Airna Raises $60M For RNA Editing Medicines

1 week from now

Jul 31, 2024 · RNA editing startup Airna is adding more funds to its Series A round, raising another $60 million as it develops genetic medicines for lung, cardiovascular, metabolic and …

biopharmadive.com

$60
OFF

AIRNA Raises Oversubscribed $60 Million Financing To Advance …

1 week from now

Jul 31, 2024 · CAMBRIDGE, Mass. & TÜBINGEN, Germany, July 31, 2024 -- (BUSINESS WIRE)--AIRNA, a biotech company pioneering RNA editing therapeutics to restore the health of …

yahoo.com

$60
OFF

AIRNA Secures $60M For Lead RNA-Editing Therapy Clinical Trials

1 week from now

Aug 8, 2024 · AIRNA, a burgeoning player in the arena of nucleic acid editing technologies, has recently secured an additional $60 million in funding, elevating its series A total to $90 million. …

patsnap.com

$60
OFF

AIRNA Raises Oversubscribed $60 Million Financing To Advance …

1 week from now

Jul 31, 2024 · CAMBRIDGE, Mass. & TÜBINGEN, Germany-- (BUSINESS WIRE)--AIRNA, a biotech company pioneering RNA editing therapeutics to restore the health of patients with …

businesswire.com

$60
OFF

AIRNA Closes $60M Series A Round To Advance RNA Editing …

1 week from now

Aug 8, 2024 · AIRNA secures $60M in oversubscribed Series A financing. Funding led by Forbion with key investments from Ono Venture, Alexandria, ARCH Venture Partners, and ND Capital. …

sliceofhealthcare.com

$60
OFF

Forbion Leads Oversubscribed $60 Million Financing In AIRNA To …

1 week from now

Jul 31, 2024 · The proceeds from the Series A financing will be used to advance AIRNA’s lead product candidate into clinical trials and further develop AIRNA’s broad pipeline. ... chemistry, …

forbion.com

$60
OFF

AIRNA Raises $60M To Develop RNA-Editing Pipeline, Advance …

1 week from now

Aug 2, 2024 · Cambridge, Massachusetts-based AIRNA will use the proceeds to advance its lead product candidate for alpha-1 antitrypsin deficiency (AATD), an inherited genetic disease …

precisionmedicineonline.com

$60
OFF

RNA Editing Therapy Developer Closes $60M Series A Financing

1 week from now

Jul 31, 2024 · A developer of RNA editing therapies whose lead program targets Alpha-1 antitrypsin deficiency (AATD) said today it has closed an oversubscribed $60 million Series A …

genengnews.com

$60
OFF

AIRNA Raises Oversubscribed $60 Million Financing To Advance …

1 week from now

Jul 31, 2024 · CAMBRIDGE, Mass. & TÜBINGEN, Germany– AIRNA, a biotech company pioneering RNA editing therapeutics to restore the health of patients with rare and common …

blstimes.com

$60
OFF

Airna Biotech Secures $60M For RNA Editing Drugs

1 week from now

Aug 8, 2024 · Airna launched in September last year with an initial funding of $30 million, aiming to create a treatment for alpha-1 antitrypsin deficiency (AATD), a rare inherited disorder. …

patsnap.com

$60
OFF

Airna Raises $60M Financing - FinSMEs

1 week from now

Jul 31, 2024 · Airna, a Cambridge, MA-based biotech company advancing RNA editing therapeutics to restore the health of patients with rare and common diseases, closed a $60m …

finsmes.com

$60
OFF

Breaking News: AIRNA Secures $60 Million In Series A Funding To ...

1 week from now

We are thrilled to announce that AIRNA, a groundbreaking biotech company at the forefront of RNA editing therapeutics, has successfully raised $60 million in its latest funding round. This …

leadsontrees.com

$60
OFF

RNA Editing Therapy Developer Closes $60M Series A Financing

1 week from now

Jul 31, 2024 · A developer of RNA editing therapies whose lead program targets Alpha-1 antitrypsin deficiency (AATD) said today it has closed an oversubscribed $60 million Series A …

packgene.com

$30
OFF

AIRNA Emerges From Stealth With $30M Financing – SPARK Stanford

1 week from now

Sep 26, 2023 · AIRNA, a startup company co-founded by SPARK scholars Dr. Jin Billy Li and Dr. Paul Vogel, emerged from stealth with a $30 million financing round led by ARCH Venture …

stanford.edu

FAQs about AIRNA Raises Oversubscribed $60 Million Financing to Advance … Coupon?

Will airna be able to treat AATD?

Airna is part of a recent cohort of biotechnology companies trying to develop a treatment for AATD. One of its competitors, Wave Life Sciences, said in early September that it planned to dose the first person in its clinical trial for an RNA editing therapy for AATD by the end of the year. ...

Will RNA editing lead the next generation of RNA therapeutics?

“RNA editing is poised to lead the next generation of RNA therapeutics by targeting diseases not accessible through other approaches with a medicine that can be delivered to large patient populations,” said Kris Elverum, president and CEO of AIRNA. ...

Is airna a stealth company?

AIRNA, a company pioneering RNA editing therapeutics to restore the health of patients with rare and common diseases, has emerged from stealth with a $30 million initial financing led by ARCH Venture Partners. ...

Will airna develop a drug for alpha-1 antitrypsin deficiency?

Kris Elverum, the CEO of Airna, said the company is first focusing on developing a drug for alpha-1 antitrypsin deficiency Permission granted by AIRNA Airna, a biotechnology startup focused on RNA editing to make more precise medicines, emerged from stealth Tuesday with $30 million in hand. ...

What is airna & how does it work?

Airna, which was co-founded by a group of scientists including researchers at Stanford University and the University of Tübingen, looks at a protein known as ADAR, which stands for adenosine deaminase acting on RNA. The enzyme is already present in the body, helping to modify and regulate genes. ...

Who owns airna Therapeutics?

Its initial plan is to develop an experimental drug to treat the inherited disorder alpha-1 antitrypsin deficiency, or AATD. Airna’s board is chaired by Rodger Novak, one of the co-founders of CRISPR Therapeutics. Kris Elverum, a former executive at Diagon Therapeutics, Rubius Therapeutics, Turnstone Biologics and SQZ Biotech, is the company’s CEO. ...